WAYNE, Pa., July 30, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that 200,000 patients have been treated with the minimally invasive UroLift® System for benign prostatic ...

Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World Setting WAYNE, Pa., July 21, 2020 (GLOBE NEWSWIRE) -- ...

WAYNE, Pa., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced the results of four studies that were accepted at the ICS 2020 Annual Meeting – Online reinforcing the ...

WAYNE, Pa., July 01, 2022 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a leading global provider of medical technologies, today announced the results of several research studies that further ...

PLEASANTON, Calif., March 9, 2020 /PRNewswire-PRWeb/ -- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today ...

Dr. Irina Jaeger, director of urology at University Hospitals Richmond Medical Center, is making UroLift treatment for benign prostatic hypertrophy, or BPH, available in the area for the first time.

WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...

A common New Year’s resolution is to pay more attention to your health and now there’s a new procedure to assist men to monitor a serious health issue and potentially avoid major surgery. The Lovelace ...

Evidence supports the case for adopting the UroLift System for treating lower urinary tract symptoms of benign prostatic hyperplasia. The UroLift System relieves lower urinary tract symptoms, avoids ...

Teleflex’s TFX Interventional Urology portfolio is well positioned for sustained growth, led by UroLift’s expanding global footprint and strong clinical differentiation. Supported by favorable ...